epclusa Drug Patent Profile

When do Epclusa patents expire, and when can generic versions of Epclusa launch?

Epclusa is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are sixteen patents protecting this drug.

This drug has five hundred and thirty-three patent family members in fifty countries.

The generic ingredient in EPCLUSA is sofosbuvir; velpatasvir. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sofosbuvir; velpatasvir profile page.

DrugPatentWatch^® Generic Entry Outlook for Epclusa

Epclusa was eligible for patent challenges on June 28, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 10, 2028. This may change due to patent challenges or generic licensing.

There have been twenty-seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for epclusa

International Patents:	533
US Patents:	16
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	41
Drug Prices:	Drug price information for epclusa
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for epclusa
What excipients (inactive ingredients) are in epclusa?	epclusa excipients list
DailyMed Link:	epclusa at DailyMed

See drug prices for epclusa

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for epclusa

NDA:

208341

Dosage:

TABLET;ORAL

Constraining patent/regulatory exclusivity:

FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 6 YEARS OF AGE WEIGHING LESS THAN 17 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN

NDA:

214187

Dosage:

PELLETS;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for epclusa

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Drug Abuse (NIDA)	PHASE4
Lifespan	PHASE4
Peking University People's Hospital	Phase 4

See all epclusa clinical trials

Pharmacology for epclusa

Drug Class	Hepatitis C Virus NS5A Inhibitor Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Organic Anion Transporting Polypeptide 1B3 Inhibitors Organic Anion Transporting Polypeptide 2B1 Inhibitors P-Glycoprotein Inhibitors RNA Replicase Inhibitors

US Patents and Regulatory Information for epclusa

epclusa is protected by sixteen US patents and five FDA Regulatory Exclusivities.

This potential generic entry date is based on FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 6 YEARS OF AGE WEIGHING LESS THAN 17 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-002	Mar 19, 2020		RX	Yes	No					Y
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	PELLETS;ORAL	214187-002	Jun 10, 2021		RX	Yes	Yes
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-002	Mar 19, 2020		RX	Yes	No

EU/EMA Drug Approvals for epclusa

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Gilead Sciences Ireland UC	Epclusa	sofosbuvir, velpatasvir	EMEA/H/C/004210Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older (see sections 4.2, 4.4 and 5.1).	Authorised	no	no	no	2016-07-06

International Patents for epclusa

When does loss-of-exclusivity occur for epclusa?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Canada

China

Eurasian Patent Organization

European Patent Office

Hong Kong

Japan

Mexico

New Zealand

Poland

Portugal

Singapore

Slovenia

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering epclusa around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	095133
Australia	2014311827
Australia	2017276223

Supplementary Protection Certificates for epclusa

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203462	214 5029-2014	Slovakia		PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894 20140117
2203462	C300704	Netherlands		PRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117
2203462	PA2014040	Lithuania		PRODUCT NAME: SOFOSBUVIRUM; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116

Last updated: July 19, 2026

Epclusa (sofosbuvir/velpatasvir) Market Dynamics and Financial Trajectory: Pricing, Volume, Exclusivity, and Competitive Erosion

Epclusa (sofosbuvir/velpatasvir, GS-?; marketed by Gilead) is an established, fully oral direct-acting antiviral (DAA) for chronic hepatitis C that has transitioned from high-growth launch dynamics to mature-market volume driven by payer access, warehouse/contract cycles, and generic/biosimilar-like competitive pressure. The financial trajectory is now dominated by (1) declining brand pricing net of rebates, (2) steady but compressing treatment demand as fewer patients remain eligible under prior care gaps, and (3) heightened competition from authorized generics, lower-cost regimens, and formulary exclusions in some geographies.

---

What drives Epclusa sales: payer coverage, GT mix, and contracting dynamics?

Core revenue levers

Epclusa revenue is influenced by standard DAA market mechanics:

• Payer coverage and formularies: preferred regimen status and restriction language drive share within DAA classes.
• Gross-to-net pricing: Medicaid, Medicare, commercial PBM contracts, and country price controls drive sustained pressure after initial differentiation eroded.
• Genotype (GT) and cirrhosis mix: Epclusa is pangenotypic, but patient mix affects comparable regimen selection and dosing needs across alternatives.
• Service pathway speed: DAA “test-and-treat” models reduce time to cure and stabilize near-term demand but do not expand total cured populations indefinitely.

Where uptake concentrates

Epclusa’s uptake historically tracked:

• Broad geographic availability under Gilead’s licensing and local manufacturing partnerships.
• High affordability through managed entry (rebates/price concessions) in major markets.
• Real-world preference for simplified 12-week, all-oral therapy across GTs.

Contracting cycle impact

In mature HCV markets, revenue typically follows:

• Quarterly contract resets (PBMs and government programs).
• Tender cycles in ex-US markets.
• Channel inventory adjustments when lower-cost competitors enter or when authorized generic volumes ramp.

---

How has Epclusa financial performance evolved from launch to maturity?

Launch-to-maturity pattern

Epclusa’s market economics followed the typical DAA lifecycle:

• Initial surge: differentiated efficacy, simplified regimen, rapid guideline adoption.
• Normalization: competing pangenotypic or sofosbuvir/NS5A-related regimens enter and erode net pricing power.
• Mature-market consolidation: share stabilizes but unit price declines accelerate; volumes flatten relative to earlier years.

Mature-market hallmarks seen in public financial disclosures

For a brand like Epclusa, reported performance generally reflects:

• Net sales compression driven by price concessions and competitive launches.
• Reduced incremental pull-through because most eligible patients are already treated.
• Ongoing demand sustained by new diagnoses, reactivation in certain cohorts, and ongoing screening programs.

Financial trajectory drivers specific to HCV

• Curative ceiling: HCV is curative. That structure limits long-duration sustained growth after diagnosis and treatment coverage expand.
• Residual disease incidence: revenue persists but tracks new case flows and reinfection rates.
• Policy and screening intensity: changes in testing and reimbursement can shift demand quarter-to-quarter.

---

When do competitors erode Epclusa pricing and share: authorized generics, branded rivals, and formulary exclusion?

Competition taxonomy in HCV

Competitive threats in Epclusa’s class tend to arrive through three routes:

1. Lower-priced “same-category” pangenotypic regimens (oral DAAs with similar clinical endpoints).
2. Authorized generics / authorized manufacturer supply under licensing frameworks (often in countries with active patent estates and local manufacturing).
3. Tender-driven displacement in national health systems.

How displacement happens

Epclusa’s pricing and share typically weaken when:

• A rival regimen becomes preferred due to lower net cost.
• Formulary tiering moves Epclusa down.
• Tender awards shift volume toward the lowest compliant bid.

Implications for financial trajectory

• Early-stage competitive entry compresses net pricing first; brand share follows if payer behavior changes.
• Once multiple regimens are eligible, the limiting factor becomes budget impact rather than clinical advantage.

---

What patents protect Epclusa, and how do they affect market duration?

Epclusa’s protection landscape is defined by multiple patent families covering:

• Active ingredient composition(s) (sofosbuvir, velpatasvir) and their combination.
• Combination claims and potentially specific salt/polymorph/crystal forms.
• Method-of-treatment claims (cirrhosis, prior treatment status, genotype coverage, ribavirin or no-ribavirin usage).
• Formulations and manufacturing/process claims.

Net effect on market duration: patent estates shape exclusivity windows, authorized generic timelines, and the timing of generic entry in specific jurisdictions.

Why patent timing matters economically

When combination product patents or formulation protections end:

• Generic and authorized supply increases.
• Tender leverage increases for payers.
• Net price declines accelerate.

---

What is the Orange Book status of Epclusa, and does it limit generic entry?

Epclusa is an FDA-approved combination product. Orange Book exclusivity listings (where applicable) and patent codes influence:

• Paragraph IV challenge timing (if ANDAs are filed for generics).
• 60-month stay risk if challenges lead to litigation.
• Design-around routes if remaining patents are method or formulation-specific.

Economic outcome

• Patent-maintained exclusivity sustains higher net pricing early.
• As Orange Book-listed protection wanes, the market typically shifts to price competition rather than clinical differentiation.

---

How strong is the patent estate for Epclusa versus generic entry risk?

Patent estate structure that usually drives risk

For combination DAAs, the strongest estates tend to include:

• Composition-of-matter and combination claims that prevent direct generics.
• Method-of-use claims that constrain “label-to-label” substitution where remaining claims are still active.
• Formulation claims that block certain dosage/process workarounds.

Generic entry risk in practice

Even when some patents expire:

• Remaining claims can delay a full generic substitution.
• Payers can still switch through therapeutically equivalent alternatives not blocked by remaining patents.

Market impact

The financial trajectory shifts once generic entry or authorized generic substitution becomes payer-acceptable at scale: that is when net revenue declines typically steepen.

---

What patent litigation affects Epclusa, and how do settlements change market timing?

In HCV drug classes, litigation and settlement agreements usually determine:

• Launch dates for ANDA competitors,
• Design-around boundaries,
• Geographic scope (where settlement covers supply),
• Injunction scope.

Commercial effect of litigation outcomes

• Litigation delays shift competition to later quarters, smoothing revenue decline.
• Settlements can bring earlier low-cost supply if they define “carve-outs” that allow market entry.

---

How does Epclusa compare with competing hepatitis C regimens in commercial positioning?

Positioning dimensions that affect share

• Pangenotypic coverage: reduces regimen complexity for prescribers.
• Treatment duration simplicity: 12-week standard course reduces workflow burden.
• Renal impairment and cirrhosis performance: affects eligibility.
• Drug-drug interaction profile: drives payer and provider comfort.

Market share dynamics

Epclusa’s share typically holds better than narrow genotype regimens during competition because pangenotypic regimens are easier to standardize for payers. Over time, however, pricing becomes the dominant driver once multiple pangenotypic options are established.

---

Does Epclusa face biosimilar-like threats, or is competition purely generic?

Epclusa is a small-molecule combination DAA, not a biologic. That means:

• Biosimilar frameworks do not apply.
• Competitive pressure comes from generics/authorized generics and alternative branded DAAs.

---

What manufacturing and supply-chain barriers determine Epclusa’s ability to hold market share?

Supply considerations in matured DAA markets

• Complexity of active pharmaceutical ingredient (API) synthesis and procurement can affect supply assurance.
• Bulk availability through authorized local manufacturing can reduce barrier to entry for licensed competitors.
• Packaging and distribution logistics matter when tender awards are frequent.

Why this affects financial trajectory

Even when clinical differentiation is limited, supply stability reduces the risk of:

• stock-outs that force prescriber switch,
• lost tender wins,
• channel inventory corrections.

---

How much revenue exposure does Epclusa face from US versus ex-US pricing erosion?

US pricing erosion

• US net pricing is heavily influenced by rebates and PBM contracts.
• As competing DAAs gain preferred status, Epclusa’s incremental contribution tends to decline.

Ex-US pricing erosion

• Many ex-US markets use tendering and/or regulated pricing.
• Licensed manufacturing and authorized generics can pressure brand pricing earlier or more consistently by route-to-market.

---

Key competitive scenarios for Epclusa: what happens to sales if payer switches accelerate?

Scenario A: Gradual substitution

• Net price declines continue, volume stays stable.
• Financial trajectory shows steady maturity rather than abrupt decline.

Scenario B: Tender-driven displacement

• Rapid formulary change or tender shift causes volume loss.
• Brand revenues drop faster than net price alone would predict.

Scenario C: Multiple low-cost entrants

• Payer bargaining power rises.
• Price compression accelerates and share fragmentation increases.

---

Key Takeaways

• Epclusa’s market dynamics now reflect mature DAA economics: curing is a finite demand pool, so revenue growth is replaced by unit price compression and share management through payer contracts.
• Competitive erosion typically follows a sequence: net pricing pressure first, then formulary displacement when lower-cost regimens become preferred.
• Protection impacts revenue duration by shaping the timing of generic/authorized supply and by constraining substitution through Orange Book-listed patents and litigation outcomes.
• Financial trajectory is most sensitive to contract cycles, tender decisions, and the pace of payer switching within pangenotypic DAA classes.

---

FAQs

1) What drives Epclusa sales in Medicaid and Medicare versus commercial plans?

Rebate structures, formulary tier placement, and managed entry agreements determine net price and preferred regimen status, usually leading to stronger price compression over time in government programs.

2) Does cirrhosis or prior treatment status affect Epclusa utilization patterns commercially?

Yes. Patient eligibility language in coverage policies and restriction criteria influences uptake, especially as alternative regimens can be cheaper for specific subpopulations.

3) Are there formulation changes or line extensions for Epclusa that alter competitive pricing?

Line extensions can matter for lifecycle management, but mature competition usually drives net pricing down regardless of minor formulation differentiation unless claims or supply arrangements provide coverage advantage.

4) How quickly do generics substitute once restrictions lift?

In pangenotypic HCV, substitution can be fast when payers standardize procurement, but it is moderated by tender cadence, physician behavior, and channel inventory timing.

5) What is the main commercial risk to Epclusa during patent expiration windows?

The main risk is not just clinical equivalence. It is payer acceptance of lower-cost supply (generic/authorized generic or alternative DAAs) that triggers rapid net price declines and volume reallocation.

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
2. FDA labeling and prescribing information for Epclusa (sofosbuvir/velpatasvir). U.S. Food and Drug Administration. (Accessed 2026).
3. Gilead Sciences. Quarterly financial reports and investor materials discussing hepatitis C franchise performance. (2017-2025; accessed 2026).

DrugChatter Q&A for EPCLUSA

When does epclusa expire patent?
Epclusa patent expiration?
Why is the retail price of epclusa so high compared to other countries?
Epclusa generic availability?
Epclusa cost with insurance?